Table 3.

Overall and disease-free survival: impact of TN category and treatment

TN Category	Overall Survival
	RT plus 5-FU/MMC arm				RT plus 5-FU/CDDP arm
	TD/No. of Patients	5y-%‡	HR (95% CI)	P value†	TD/No. of Patients	5y-%	HR (95% CI)	P value†
Node negative
T2N0	28/161	86	1.00		48/162	78	1.00
T3N0	15/51	74	1.79 (0.96-3.35)	.07	15/45	74	1.28 (0.72, 2.29)	.40
T4N0	4/15	77	1.63 (0.57-4.65)	.36	10/16	37	2.95 (1.49-5.86)	.002
Node positive
T2N1-3	14/46	83	1.85 (0.97-3.51)	.061	24/53	59	1.81 (1.11-2.95)	.018
T3N1-3	9/21	57	3.14 (1.48-6.66)	.0029	11/25	57	1.93 (1.00-3.72)	.049
T4N1-3	13/18	37	7.08 (3.65-13.75)	<.0001	3/7	54	1.53 (0.48-4.90)	.48
P value*	<.0001				.013
TN Category	Disease-Free Survival
	RT plus 5-FU/MMC arm				RT plus 5-FU/CDDP arm
	TF/No. of Patients	5 y %‡	HR (95% CI)	P value†	TF/No. of Patients	5y-%	HR (95% CI)	P value†
Node Negative
T2N0	42/161	80	1.00		68/162	65	1.00
T3N0	23/51	60	1.94 (1.17-3.23)	.011	22/45	62	1.30 (0.80-2.10)	.29
T4N0	5/15	65	1.44 (0.57-3.65)	.44	11/16	36	2.56 (1.35-4.85)	.004
Node Positive
T2N1-3	20/46	68	1.86 (1.09-3.17)	.023	30/53	49	1.63 (1.06-2.51)	.025
T3N1-3	12/21	43	3.27 (1.72-6.23)	.0003	17/25	34	2.62 (1.54-4.47)	.0004
T4N1-3	14/18	27	5.64 (3.06-10.38)	<.0001	4/7	43	1.75 (0.64-4.79)	.28
P value*	<.0001				.0015

Abbreviations: CDDP = cisplatin; CI = confidence interval; HR = hazard ratio; MMC = mitomycin; TF = total failures.

^*P value from the log–rank test.

^†P value from χ² test using the Cox proportional hazards model.

^‡Some 5-year estimates might be unstable due to small sample sizes and therefore, too few patients at risk at 5 years.